人民财讯9月22日电，企查查APP显示，近日，贵州茅台（600519）生物科技研发有限责任公司成立， 法定代表人为杨帆，注册资本10亿人民币，经营范围含生物化工产品技术研发、发酵过程优化技术研 发、工业酶制剂研发、细胞技术研发和应用、生物农药技术研发等。企查查股权穿透显示，该公司由中 国贵州茅台酒厂(集团)有限责任公司、贵州茅台共同持股。 ...

IT之家 9 月 22 日消息，贵州茅台生物科技研发有限责任公司于 9 月 19 日成立，法定代表人为杨帆，注 册资本 10 亿元人民币，经营范围包括生物化工产品技术研发、发酵过程优化技术研发、工业酶制剂研 发、细胞技术研发和应用、生物农药技术研发等。 根据《2025 凯度 BrandZ 最具价值中国品牌 100 强》榜单，白酒巨头茅台以 800.23 亿美元（IT之家注： 现汇率约合 5694.21 亿元人民币）品牌价值稳居季军，前两名分别为腾讯、阿里巴巴。 股东信息显示，该公司由中国贵州茅台酒厂 (集团) 有限责任公司、贵州茅台酒股份有限公司共同持 股。 ...

南模生物上市首日盘中最高价报82.00元，为该股上市以来最高价。 南模生物首次公开发行股票募集资金总额为16.49亿元，扣除发行费用后募集资金净额为14.68亿元。南 模生物最终募集资金净额比原计划多10.68亿元。南模生物于2021年12月23日披露的招股说明书显示， 该公司拟募集资金4.00亿元，分别用于上海砥石生物科技有限公司生物研发基地项目(南方模式生物)、 基因修饰模型资源库建设项目、人源化抗体小鼠模型研发项目、基于基因修饰动物模型的药效平台建设 项目、补充流动资金项目。 南模生物首次公开发行股票的发行费用总额为1.81亿元，其中，保荐及承销费用1.58亿元。 中国经济网北京9月10日讯南模生物(688265.SH)今日股价下跌，截至收盘，该股报54.64元，跌幅 4.09%。该股目前处于破发状态。 南模生物于2021年12月28日在上交所科创板上市，发行股票数量为1949.09万股，发行价格为84.62元/ 股，保荐人(主承销商)为海通证券股份有限公司(现更名为国泰海通证券股份有限公司)，保荐代表人为 张子慧、陈亚聪。 ...

Fundraising Overview - The company raised a total of RMB 1,649,319,958.00 by issuing 19,490,900 shares at a price of RMB 84.62 per share, with a net amount of RMB 1,467,876,199.92 after deducting issuance costs [1][2] - As of June 30, 2025, the total net amount of raised funds was RMB 146,787.62 million, with RMB 146,308.22 million invested in projects and RMB 1,794.24 million in net interest income [1][2] Fund Management - The company established a management method for the raised funds, adhering to regulations to ensure proper management and usage, including a dedicated account storage system [1][2] - Six dedicated accounts for the raised funds have been closed as of June 30, 2025, indicating a complete utilization of the funds [1][2] Fund Utilization - The company did not have any idle funds or temporary use of idle funds for working capital during the reporting period [1][2] - All investment projects funded by the raised capital, including the "Gene Modification Model Resource Library" and "Humanized Antibody Mouse Model Development," have been completed [4][5] Cash Management - The company approved the use of up to RMB 80 million of excess and idle funds for cash management, allowing for cyclical use within a 12-month period starting from February 1, 2024 [1][2] Compliance and Reporting - The company confirmed that all disclosed information regarding the use of raised funds is timely, truthful, accurate, and complete, with no significant violations in fund usage [1][2]